As of June 30, 2023, Pyxis Oncology had cash and cash equivalents and short-term investments of $144.1 million which is expected to fund operations into the first half of 2025 and reflects continued financial discipline.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PYXS:
- PYXS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update
- Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference
- Pyxis Oncology initiated with a Buy at EF Hutton
- Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)